MedTrace Logo

Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment

NCT04673214 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2021-08-16

Study results available
· View outcomes & findings →

Summary

The present study is designed for patients with mild COVID-19 phase, to demonstrate if there is a modification in the clinical evolution greater than or equal to 25% in their symptoms, implemented in two groups of patients under an early intervention treatment, a group ( A) will receive Azithromycin / Ivermectin / Ribaroxaban / Paracetamol and another group (B) will receive Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call

Conditions

  • Covid19

Interventions

DRUG

Azithromycin / Ivermectin / Ribaroxaban / Paracetamol

In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group A of Azithromycin / Ivermectin / Ribaroxaban / Paracetamol to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily

DRUG

Azithromycin / Ribaroxaban / Paracetamol

In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group B of Azithromycin / Ribaroxaban / Paracetamol, to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily

Sponsors & Collaborators

  • Coordinación de Investigación en Salud, Mexico

    collaborator OTHER_GOV

  • Gilberto Cruz Arteaga

    lead OTHER_GOV

Principal Investigators

  • GILBERTO CR ARTEAGA, specialist · MEXICAN SOCIAL SECURITY INSTITUTE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-16
Primary Completion
2021-02-25
Completion
2021-02-25

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04673214 on ClinicalTrials.gov